KiTZ Clinical Trial Unit (ZIPO)
Head: Prof. Dr. med. Olaf Witt
Deputy head: Prof. Dr. med. Stefan Pfister
Im Neuenheimer Feld 430
Once children and adolescents suffer a disease relapse, despite first-line therapy and intensive pre-treatment, their chances of recovery are often limited ̶ especially in the case of solid tumors or brain tumors. Thanks to far-reaching developments in molecular genetic analysis and a large number of new so-called targeted drugs and immunotherapeutic approaches, we are confident to better help these children in the near future.
Selpercatinib, a RET-Inhibitor for children with solid tumours and brain tumours
Olaparib for children with solid tumors with HRR mutations